Q4 2025 Tandem Diabetes Care Inc Earnings Call Transcript
Key Points
- Tandem Diabetes Care Inc (TNDM) surpassed $1 billion in sales for 2025, marking a significant milestone.
- The company achieved double-digit growth and improved profitability, with a 12% increase in worldwide sales.
- Tandem expanded its international operations, successfully transitioning to direct commercial operations in the UK, Switzerland, and Austria.
- The launch of new technologies, such as Control-IQ+ and FreeStyle Libre 3 Plus, contributed positively to growth.
- The company plans to launch Mobi Tubeless, the world's first patch pump with extended wear technology, in the second half of 2026.
- The transition to a pay-as-you-go reimbursement model is expected to create near-term sales headwinds of $70 million to $80 million in 2026.
- The shift to direct operations internationally involves a $15 million headwind due to distributor destocking and inventory buybacks.
- The company anticipates a moderated sales growth in 2026 due to the transition to the pharmacy channel.
- There is a risk of attrition as customers may not have the same lock-in periods as with DME, although Tandem is confident in customer retention.
- The transition to the new business model may impact revenue recognition, as sales will be recognized over time rather than upfront.
Good day, and thank you for standing by. Welcome to the Tandem Diabetes Care fourth-quarter 2025 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Susan Morrison, Executive Vice President and Chief Administrative Officer. Please go ahead.
Hello, and welcome to Tandem's fourth-quarter and year-end 2025 earnings call.
Today's discussion will include forward-looking statements. These statements reflect management's expectations about future events, our product pipeline, development time lines and financial performance and operating plans and speak only as of today's date. There are risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in our forward-looking statements, which are described in our press release issued earlier today and under the Risk Factors portion
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
